| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
L-012 is a chemiluminescent probe, not a pharmacological agent with a specific biological target. It reacts with ROS including hydroxyl radicals, hypochlorite, superoxide anion, and peroxynitrite, producing chemiluminescence proportional to ROS levels. It is used to quantify oxidative burst in neutrophils, detect ROS in biological fluids, and image inflammation in vivo.
|
|---|---|
| ln Vitro |
In vitro, L-012 reacts with various ROS types generated by activated neutrophils in human blood and oral cavity samples, producing strong chemiluminescence. It detects superoxide anion and peroxynitrite in model systems and mitochondria. The assay is highly sensitive and permits studies on ROS generation in complex biological systems.
|
| ln Vivo |
In vivo, L-012 has been used for in vivo imaging of reactive oxygen and nitrogen species in inflammation models. It enables real-time visualization of ROS/RNS production in living animals, providing a non-invasive method for assessing oxidative stress in inflammatory diseases.
|
| Enzyme Assay |
Cell-free ROS detection assay: L-012 is added to a cell-free system containing ROS-generating enzymes (e.g., xanthine oxidase) or chemical ROS sources. Chemiluminescence is measured continuously using a luminometer or plate reader. Signal intensity is proportional to ROS concentration, and specificity for different ROS species is determined using selective inhibitors.
|
| Cell Assay |
Neutrophil oxidative burst assay: human blood or isolated neutrophils are activated with stimulants (e.g., PMA, fMLP) in the presence of L-012. Chemiluminescence is measured in real-time using a luminometer. The assay quantifies ROS production by activated neutrophils and can be used to evaluate inhibitors of NADPH oxidase or myeloperoxidase.
|
| Animal Protocol |
In vivo ROS imaging: L-012 is administered systemically to inflammation model animals, and chemiluminescence imaging is performed using a charge-coupled device (CCD) camera. Signal intensity is quantified in regions of interest and correlated with inflammation severity. The technique enables non-invasive assessment of oxidative stress in living animals.
|
| References |
|
| Molecular Formula |
C13H9CLN4O2
|
|---|---|
| Molecular Weight |
288.691
|
| Exact Mass |
288.041
|
| CAS # |
143323-55-1
|
| Related CAS # |
L 012 sodium salt; 143556-24-5
|
| PubChem CID |
126741
|
| Appearance |
Light yellow to yellow solid
|
| Density |
1.487g/cm3
|
| Index of Refraction |
1.671
|
| LogP |
2.919
|
| tPSA |
105.15
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
20
|
| Complexity |
413
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1NNC(=O)C2C(=C(C3C=CC=CC=3)N=C(Cl)C1=2)N
|
| InChi Key |
ABEDICJFYSFCHB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H9ClN4O2/c14-11-8-7(12(19)17-18-13(8)20)9(15)10(16-11)6-4-2-1-3-5-6/h1-5H,15H2,(H,17,19)(H,18,20)
|
| Chemical Name |
8-amino-5-chloro-7-phenyl-2,3-dihydropyrido[3,4-d]pyridazine-1,4-dione
|
| Synonyms |
L 012; L-012; L012
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~346.4 mM; with ultrasonication and warming by heating to 60°C)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4639 mL | 17.3196 mL | 34.6392 mL | |
| 5 mM | 0.6928 mL | 3.4639 mL | 6.9278 mL | |
| 10 mM | 0.3464 mL | 1.7320 mL | 3.4639 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
